AUTHORS
Ruifeng Sun, BS, Jaewoong Lee2, Mark E Robinson, PhD3, Kohei Kume, PhD4, Zhangliang Cheng, BSc5, Kadriye Nehir Cosgun, PhD6, Song Wu, PhD7, Ning Ma, PhD8, Huimin Geng, PhD9, Joo Song, MD10, Wing C Chan, MD11, Daniel J Hodson, MD, PhD12, Matthew S Davids, MD, MMSc13, Nagarajan Vaidehi, PhD14, Markus Müschen, MD-PhD15
AFFILIATIONS
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, School of Biosystems and Biomedical Sciences, College of Health Science, Interdisciplinary Program in Precision Public Health, Seoul, Korea, Rep. of South
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
7 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
8 Department of Computational & Quantitative Medicine, Duarte, California, United States
9 Department of Laboratory Medicine, San Francisco, California, United States
10 Department of Pathology, Duarte, California, United States
11 Department of Pathology, Duarte, California, United States
12 Wellcome MRC Cambridge Stem Cell Institute and Department of Haematology, Cambridge, United Kingdom
13 Division of Lymphoma, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Department of Computational & Quantitative Medicine, Duarte, California, United States
15 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
ABSTRACT
Background and significance. Activated B-cell–like diffuse large B-cell lymphoma (ABC-DLBCL) is characterized by chronic active B-cell receptor (BCR) signaling, frequent activating mutations in CD79A and CD79B, and recurrent lesions affecting negative regulators of the BCR pathway. Unlike other protein kinase C family members, PKCδ negatively regulates immune activation. Mice lacking PKCδ develop B-cell lymphoproliferation, defective tolerance, and systemic autoimmunity, whereas humans with inherited loss-of-function PRKCD mutations develop monogenic systemic lupus erythematosus and autoimmune lymphoproliferative syndrome type III, characterized by chronic germinal center (GC) B-cell activation. Although somatic PRKCD lesions occur in approximately 10% of DLBCL cases, how PKCδ restrains BCR signaling remains unknown.
Results. We identified a previously unrecognized feedback circuit that restrains BCR signaling in activated and GC B cells and is frequently disrupted in DLBCL. This circuit coordinates PKCδ, the inhibitory phosphatases SHP1 and SHIP1, and the surface receptor CD25 to assemble inhibitory complexes proximal to the BCR.
Proteomic analysis revealed strong induction of PKCδ and CD25 following BCR engagement. Genetic perturbation in murine and human B cells identified both proteins as negative regulators of BCR and NF-κB signaling. RNA-sequencing and phosphoproteomic analyses showed that ablation of PKCδ or CD25 activated NF-κB transcriptional programs and induced hyperphosphorylation of multiple BCR pathway components. Conversely, loss of either protein diminished phosphorylation of SHP1 and SHIP1.
Mechanistically, oncogenic BCR signaling induced PKCδ-dependent phosphorylation of S268 and T271 within the cytoplasmic tail of CD25, a cytokine receptor chain best known for its role in IL-2 signaling in T and NK cells. To determine the functional importance of these sites, we used homology-directed repair to introduce knock-in alleles encoding either wild-type CD25 or a phosphorylation-deficient CD25-S268A/T271V mutant (CD25-AV) into human GC B cells. CD25-AV cells failed to terminate BCR signaling and exhibited autonomous Ca²⁺ oscillations, increased expression of CD69, CD80, and CD86, and constitutive NF-κB activation. In competitive coculture assays, CD25-AV cells rapidly outcompeted their wild-type counterparts. Interactome studies and molecular-dynamics simulations further demonstrated that PKCδ-dependent CD25 phosphorylation retains inhibitory phosphatases near BCR signaling complexes, thereby attenuating BCR signaling.
To determine the functional significance of CD25-mediated proximity between CD22-associated inhibitory phosphatases and the BCR, we developed a novel bispecific tandem diabody targeting the extracellular domains of CD22 and the BCR-signaling chain CD79B using VH/VL pairs derived from epratuzumab and polatuzumab. This compact, Fc-free antibody directly recruits CD22 to the BCR complex. Whereas anti-CD22 alone had modest effects and failed to curb the hyperactive, prolonged Ca²⁺ response in CD25-/- GC B cells, the anti-CD22×CD79B diabody profoundly inhibited Ca²⁺ signaling and reduced proliferation. Thus, enforced proximity between CD22 and CD79B restored BCR inhibition in CD25-/- GC B cells.
DLBCL cells frequently harbored lesions affecting this negative-feedback circuit. The promoter regions of PRKCD, PTPN6, and CD25 were hypermethylated in DLBCL compared with primary naïve and GC B cells, IGHV-unmutated chronic lymphocytic leukemia cells, and mantle cell lymphoma cells. Immunofluorescence analysis of human tissue microarrays revealed defective PKCδ and SHP1 expression in DLBCL, contrasting with their abundant expression in normal spleen, reactive lymphoid hyperplasia, and chronic lymphocytic leukemia. DLBCL cells also consistently failed to upregulate CD25 following BCR engagement, indicating recurrent disruption of this inhibitory pathway. Defective assembly of PKCδ-induced inhibitory complexes was additionally restored by chemically induced heterodimerization that recruited SHP1 to the BCR.
Conclusions. These findings establish that PKCδ-mediated CD25 phosphorylation is required and sufficient to assemble inhibitory complexes proximal to the BCR and thereby restrain BCR and NF-κB signaling. This feedback circuit maintains GC B-cell immune homeostasis but is frequently subverted during DLBCL lymphomagenesis through mutations and promoter hypermethylation affecting PRKCD, PTPN6, and CD25.
DISCLOSURES
Ruifeng Sun, BS: No relevant conflicts of interest to declare.